| Detected | Trial | Change |
|---|---|---|
| 2026-07-29 | NCT07204340 TLN-372 in Advanced KRAS Mutant Solid Tumors |
Enrollment increased: 240 -> 270 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-20 | NCT07713732 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1 | |||
| NCT06733441 | A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma | Lymphoma | Recruiting |
| NCT07082803 | TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Lymphoma | Recruiting |
| NCT07204340 | TLN-372 in Advanced KRAS Mutant Solid Tumors | KRAS Mutant Solid Tumors | Recruiting |
| NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Small Cell Lung Cancer ( SCLC ) | Not Yet Recruiting |